Summary & Overview
HCPCS A9599: Beta-Amyloid PET Radiopharmaceutical, Per Study Dose
HCPCS Level II code A9599 designates a diagnostic radiopharmaceutical used for beta-amyloid PET imaging, billed per study dose. Beta-amyloid PET scans are increasingly used in clinical and research settings to detect amyloid plaque associated with Alzheimer’s disease and related disorders, making accurate coding important for clinical documentation, payer adjudication, and national utilization tracking. Key national payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, common settings where the service is delivered, and the policy and reimbursement context that typically surrounds radiopharmaceuticals for neuroimaging. The publication summarizes benchmark pricing and coverage patterns across major payers, highlights recent policy developments affecting access to beta-amyloid PET imaging, and explains clinical context relevant to coding and billing for per-study radiopharmaceutical charges. Where available, related coding considerations and payer-specific coverage notes are summarized. Data not available in the input.
Billing Code Overview
HCPCS Level II code A9599 describes a radiopharmaceutical, diagnostic, for beta-amyloid positron emission tomography (PET) imaging, per study dose, not otherwise specified. This code is used to report the radiotracer dose administered for beta-amyloid PET studies that evaluate amyloid plaque in the brain.
-
Service type: Diagnostic radiopharmaceutical administration for beta-amyloid PET imaging
-
Typical site of service: Outpatient imaging centers, hospital outpatient departments, and ambulatory care centers where PET imaging is performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65–80-year-old adult with progressive cognitive decline, ambiguous mild cognitive impairment, or suspected Alzheimer disease where amyloid pathology status will change management. The ordering neurologist or memory disorders specialist evaluates history, cognitive testing, and neuroimaging (MRI or CT) before ordering a beta-amyloid PET study. The patient presents to an outpatient radiology or nuclear medicine department or an ambulatory infusion/diagnostic center. A nuclear medicine technologist administers the A9599 radiopharmaceutical as a single study dose per protocol, the patient undergoes PET imaging after the appropriate uptake interval, and images are reconstructed and interpreted by a board-certified radiologist or nuclear medicine physician. The final report documents radiopharmaceutical name and dose, time of injection, imaging protocol, findings regarding cortical beta-amyloid deposition, and an impression that informs diagnostic considerations such as presence or absence of amyloid deposition. Typical sites of service are outpatient hospital radiology or ambulatory imaging centers and specialized nuclear medicine clinics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing separately for physician interpretation of the PET images when the facility bills for the technical component. |